The FDA has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta.

Generating income from your investments is a nice thing. After all, you'll earn money without punching a clock and answering ...

Merit Financial Group LLC cut its holdings in shares of iShares Core High Dividend ETF (NYSEARCA:HDV – Free Report) by 18.7% ...

The FDA has granted breakthrough therapy designation to Bluejay Therapeutics’ brelovitug for the treatment of chronic hepatitis delta, for which no approved therapies currently exist in the U.S., the ...

The drug has been granted Breakthrough Therapy designation by the FDA for the treatment of chronic hepatitis delta (CHD).

Global Commercial Vehicle Outlook 2025, Global medium & heavy commercial vehicle sales were 3.3 million units in 2024 and are ...

Detailed price information for High Dividend Ishares Core ETF (HDV-A) from The Globe and Mail including charting and trades.

They are man’s best friend on a mission and are a great asset to the law enforcement agencies in. K-9 Teg and K-9 Jocko serve ...

Detailed price information for High Dividend Ishares Core ETF (HDV-A) from The Globe and Mail including charting and trades.

Bulevirtide therapy proves effective for HDV-related cirrhosis in a 96-week real-world study, showing significant liver ...

A smart beta exchange traded fund, the iShares Core High Dividend ETF (HDV) debuted on 03/29/2011, and offers broad exposure to the Style Box - Large Cap Value category of the market.

We use cookies to make your website experience better. By accepting this notice and continuing to browse our website you confirm you accept our Terms of Use & Privacy Policy.